OPM obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

DEMOCRITE Project: Demonstrating the efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel Disease

Dijon (France), April 17, 2024, at 6:00pm CEST– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announced today that it has received notice of the grant of funding associated with the “i-Démo n°2” call for projects as part of the France 2030 plan. The aim of this call for projects is to develop industrial and service companies in growth markets that create value and competitiveness for our economy and contribute to the energy, ecological and digital transitions.